PUBLICATIONS

Search by category
10.28.2020 | JCO Precision Oncology | Prostate
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer

Andrew J. Armstrong, MD, ScM1; Jun Luo, PhD2; David M. Nanus, MD3; Paraskevi Giannakakou, PhD3; Russell Z. Szmulewitz, MD4; Daniel C. Danila, MD3,5; Patrick Healy, MS; Monika Anand, PhD1; William R. Berry, MD1; Tian Zhang, MD1; Michael R. Harrison, MD1; Changxue Lu, MM, PhD2; Yan Chen, BM, PhD2; Giuseppe Galletti, MD, PhD3; Joseph D. Schonhoft, PhD7; Howard I. Scher, MD5; Richard Wenstrup, MD7; Scott T. Tagawa, MD3; Emmanuel S. Antonarakis, MD2,8; Daniel J. George, MD1; and Susan Halabi, PhD8
07.01.2020 | Clinical Cancer Research | Prostate
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy

Conteduca V, Ku SY, Puca L, Slade M, Fernandez L, Hess J, Bareja R, Vlachostergios PJ, Sigouros M, Mosquera JM, Sboner A, Nanus DM, Elemento O, Dittamore R, Tagawa ST, Beltran H.Mol Cancer Ther. 2020 May;19(5):1157-1164. DOI: 10.1158/1535-7163
07.01.2020 | Clinical Cancer Research | Prostate
Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer

Malihi PD, Graf RP, Rodriguez A, Ramesh N, Lee J, Sutton R, Jiles R, Ruiz Velasco C, Sei E, Kolatkar A, Logothetis C, Navin NE, Corn P, Aparicio AM, Dittamore R, Hicks J, Kuhn P, Zurita AJ.Clin Cancer Res. 2020 Apr 27. DOI: 10.1158/1078-0432.CCR-19-4100
05.30.2019 | JCO Precision Oncology | Prostate
Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer

Using nonenrichment-based, potentially more sensitive Epic Sciences circulating tumor cell (CTC) platform, we sought to detect and characterize CTCs in untreated, high-risk localized prostate cancer and to evaluate their clinical implication.
03.20.2019 | Science Translational Medicine | Prostate
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer

Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Science Translational Medicine 20 Mar 2019. DOI: 10.1126/scitranslmed.aav0891
03.15.2019 | Journal of Clinical Oncology | Prostate
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Published online March 13, 2019. DOI: 10.1200/JCO.18.01731 Journal of Clinical Oncology.
07.05.2018 | JAMA Oncology | Prostate
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer
Autio KA, Dreicer R, Anderson J, et al. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. JAMA Oncology. Advance Online Publication 2018 July. DOI:10.1001/jamaoncol.2018.2168
06.28.2018 | JAMA Oncology | Prostate
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer
Scher HI, Graf RP, Schreiber NA, et al. Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. JAMA Oncology. Advance Online Publication: 2018 June. DOI:10.1001/jamaoncol.2018.1621
06.19.2018 | Oncotarget | Prostate
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
Boudadi, K, Antonarakis, ES, et al. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget, 9(47). DOI:10.18632/oncotarget.25564
10.01.2017 | Cancer Research | Prostate
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer

The heterogeneity of an individual patient's tumor has been linked to treatment resistance, but quantitative biomarkers to rapidly and reproducibly evaluate heterogeneity in a clinical setting are currently lacking.
09.28.2017 | PLOS One | Breast
Androgen receptor expression on circulating tumor cells in metastatic breast cancer

Androgen receptor (AR) is frequently detected in breast cancers, and AR-targeted therapies are showing activity in AR-positive (AR+) breast cancer. However, the role of AR in breast cancers is still not fully elucidated and the biology of AR in breast cancer remains incompletely understood.
07.20.2017 | PLOS One | Lung
Detecting expression of 5T4 in CTCs and tumor samples from NSCLC patients

The fetal oncogene 5T4 is a cell surface protein, with overexpression observed in a variety of cancers as compared to normal adult tissue. The ability to select patients with tumors that express high levels of 5T4 may enrich a clinical trial cohort with patients most likely to respond to 5T4 targeted therapy.
06.02.2017 | Clinical Genitourinary Cancer | Prostate
Clinical Genitourinary Cancer

Abiraterone acetate (AA) inhibits androgen biosynthesis and prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) when combined with prednisone (P). Resistance to therapy remains incompletely understood. In this open-label, single-arm, multicenter phase II study we investigated the clinical benefit of increasing the dose of AA at the time of resistance to standard-dose therapy.
04.26.2017 | Cancer Epidemiology, Biomarkers & Prevention | Lung
Cellular expression of PD-L1 in the peripheral blood of lung cancer patients is associated with worse survival.
Boffa, D et al. Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. 2017 January. DOI: 10.1158/1055-9965.EPI-17-0120
02.10.2017 | Clinical Pharmacology & Therapeutics | CTC
Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium

The cancer community understands the value of blood profiling measurements in assessing and monitoring cancer. We describe an effort among academic, government, biotechnology, diagnostic, and pharmaceutical companies called the Blood Profiling Atlas in Cancer (BloodPAC) Project.
11.24.2016 | European Association of Urology | Prostate
Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer.

Scher, H et al. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. 2016 November. DOI:/10.1016/j.eururo.2016.11.024
11.16.2016 | PLOS One | FCP
Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis

Genomic instability is a hallmark of cancer often associated with poor patient outcome and resistance to targeted therapy. Assessment of genomic instability in bulk tumor or biopsy can be complicated due to sample availability, surrounding tissue contamination, or tumor heterogeneity.
09.22.2016 | BMC Cancer | Bladder
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.

Anantharaman, A et al. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer 201616:744 DOI: 10.1186/s12885-016-2758-3
09.18.2016 | BJU International | Prostate
Phenotypic diversity of circulating tumor cells in patients with metastatic castration-resistant prostate cancer.

McDaniel AS, et al. Phenotypic diversity of circulating tumor cells in patients with metastatic castration-resistant prostate cancer. BJU Int. 2016 Aug . doi: 10.1111/bju.13631. [Epub ahead of print]
09.08.2016 | International Journal of Molecular Sciences | CTC
Circulating tumor cells (CTC) and cell-free DNA (cfDNA) workshop 2016: Scientific opportunities and logistics for cancer clinical trial incorporation.

Lowes, LE et al. Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation. Int J Mol Sci. 2016 Sep ;17(9)
06.04.2016 | JAMA Oncology | Prostate
Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer.

Scher, H et al. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncology. Advance Online Publication: 2016 June. DOI:10.1001/jamaoncol.2016.1828
03.15.2016 | Clinical Cancer Research | Prostate
The initial detection and partial characterization of circulating tumor cells in neuroendocrine prostate cancer.

Beltran, H et al. The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. 2016 March. DOI:10.1158/1078-0432.CCR-15-0137
01.01.2016 | Journal of Circulating Biomarkers | Myeloma
Detection and Characterization of Circulating Tumour Cells in Multiple Myeloma

Multiple myeloma (MM) remains an incurable disease despite recent therapeutic improvements. The ability to detect and characterize MM circulating tumour cells (CTCs) in peripheral blood provides an alternative to replace or augment invasive bone marrow (BM) biopsies with a simple blood draw, providing real-time, clinically relevant information leading to improved disease management and therapy selection.

12.15.2015 | Clinical Cancer Research | Prostate
The initial detection and partial characterization of circulating tumor cells in neuroendocrine prostate cancer.

Beltran, et al. (2015) The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clinical Cancer Research. Author Manuscript Published OnlineFirst on December 15, 2015; DOI: 10.1158/1078-0432.CCR-15-0137

09.17.2015 | British Journal of Cancer | Prostate
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients.

Punnoose, et al. (2015) PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. British Journal of Cancer, 1–9 | doi: 10.1038/bjc.2015.332

05.13.2015 | Journal of Circulating Biomarkers | CTC
Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells

Circulating tumor cells (CTCs) analysis is a promising new diagnostic field to estimate risk and monitor treatment efficacy, metastatic relapse, and progression in cancer patients. The study aim was to isolate and characterize CTCs in blood samples of Ewing sarcoma (ES) patients exploiting two main characteristics: CD99 expression and presence of chromosomal translocations.

04.20.2015 | Journal of Circulating Biomarkers | FCP
Analytical validation and capabilities of the Epic CTC platform: enrichment-free circulating tumor cell detection and characterization.

Werner, et al (2015) Analytical validation and capabilities of the Epic CTC platform: enrichment-free circulating tumor cell detection and characterization. J circulating biomarkers 4:3. doi: 10.5772/60725